quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Datavault AI Mengumumkan Partisipasinya dalam Pameran CES 2026 dan Info Terbaru untuk Investor tentang Divisi Akustik

View original at globenewswire.com
Datavault AI Mengumumkan Partisipasinya dalam Pameran CES 2026 dan Info Terbaru untuk Investor tentang Divisi Akustik PHILADELPHIA, Dec. 31, 2025 (GLOBE NEWSWIRE) -- melalui IBN -- Datavault AI Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • VerifyU remains a core area for ongoing development and commercialization focus

    80% confidence

  • 2025 marks development and licensing partnerships with Dolby Technologies, WiSA product line advancements, innovative ADIO technology integration into events and advertising, and continued IP portfolio expansion as core company strategy

    80% confidence

  • Engineering quality and ownership of crucial intellectual property is how WiSA became the standard in acoustics, reflecting product performance excellence and a culture that extends across all of Datavault AI

    80% confidence

  • All efforts are aimed at strengthening position as the sole source of breakthrough solutions

    80% confidence

  • WiSA E adoption is increasing in decoder applications and premium audio products globally, supporting wider market penetration

    80% confidence

Data points we hold from this source

Datavault AI Inc. · patent count63 patents
Datavault AI Inc. · new patents published9 patents
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Datavault AI Mengumumkan Partisipasinya dalam Pameran CES 2026 dan Info Terbaru untuk Investor tentang Divisi Akustik — Source | Via News | pt.VIA.NEWS